Evaluation of the pharmacokinetic interaction between the β3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects

Clinical Pharmacology in Drug Development

Volumn 2, Issue 3, 2013, Pages 255-263

  Krauwinkel, Walter J J ^a   Kerbusch, Virginie M M ^b   Meijer, John ^a   Tretter, Reiner ^a   Strabach, Gregory ^c   Van Gelderen, E Marcel ^a  

^a Astellas Pharma Global Development   (Netherlands)

^b PharmAspire Consulting   (Netherlands)

^c SOCIÉTÉ GÉNÉRALE   (France)

Author keywords

Interaction; Mirabegron; Pharmacokinetic; Solifenacin

Indexed keywords

MIRABEGRON; SOLIFENACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; DRY EYE; DYSMENORRHEA; DYSPEPSIA; EPISTAXIS; ERYTHEMA; FEMALE; FLATULENCE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; JOINT DISLOCATION; MALE; MAXIMUM PLASMA CONCENTRATION; MENSTRUATION DISORDER; MONOTHERAPY; NORMAL HUMAN; PELVIS PAIN SYNDROME; PLASMA CONCENTRATION-TIME CURVE; PRESYNCOPE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; XEROSTOMIA;

EID: 84891967370     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.37     Document Type: Article

References (21)

1. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med. 1999; 44(2):56-66.
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002C terminology report: the ongoing debate. Neurourol Urodyn. 2009; 28(4):287.
3. Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011; 2011:820816.
4. 3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26(6):752-756.
5. Takusagawa S, Scheinkoenig J, Buckley D, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron (YM178), a potent and selective ß3-adrenoceptor agonist. Xenobiotica. 2012; 42(12):1187-1196.
6. Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009; 48(5):281-302.
7. 14C] mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012; 40(4):815-824.
8. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron (YM178), a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012; 42(10):957-967.
9. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5):565-578.
10. Harrington AM, Hutson JM, Southwell BR. Cholinergic neurotransmission and muscarinic receptors in the enteric nervous system. Prog Histochem Cytochem. 2010; 44(4):173-202.
11. Bharucha AE, Ravi K, Zinsmeister AR. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010; 299(1):G215-G219.
12. Teijlingen R, Meijer J, Takusagawa S, Gelderen M, Beld C, Usui T. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 887-888:102-111.
13. U.S., Food and Drug Administration (FDA). Guidance for Industry. Drug interaction studies-Study design, data analysis, and implications for dosing and labeling. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf Accessed October 16.
14. European Medicines Agency. Guideline on the investigation of bioequivalence. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf Accessed October 16.
15. i values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 2009; 37(Web Server issue):W441-W445.
16. Dickinson J, Lewand M, Sawamoto T, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Invest. 2013; 33(1):11-23.
17. Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic properties of mirabegron, a beta(3)-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012; 34(10):2144-2160.
18. European Medicines Agency. Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf Accessed October 16.
19. Chiba T, Bharucha AE, Thomforde GM, Kost LJ, Phillips SF. Model of rapid gastrointestinal transit in dogs: effects of muscarinic antagonists and a nitric oxide synthase inhibitor. Neurogastroenterol Motil. 2002; 14(5):535-541.
20. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull. 2007; 30(1):54-58.
21. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004; 93(1):71-77.